본문 바로가기
KERD
논문KCI 등재

비정형 항정신병약물 사용과 신경이완제 악성 증후군: 임상적 관점 기반 종설

Atypical Antipsychotics Use and Neuroleptic Malignant Syndrome: A Review With a Clinical Perspective

김가영
대한조현병학회 (Korean Academy of Schizophrenia)|2024.10|대한조현병학회지 (Korean Journal of Schizophrenia Research)|제27권 제2호|pp. 29-34

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Atypical antipsychoticsNeuroleptic malignant syndromeCatatoniaLorazepamSerotonin syndrome.
주제분류정신과학

초록

Neuroleptic malignant syndrome (NMS) is a potentially life-threatening idiosyncratic reaction associated with the use of antipsychotic medications, characterized by hyperthermia, muscle rigidity, and alterations in consciousness. Despite a reduction in its incidence due to the predominance of atypical antipsychotics in contemporary treatment regimens, NMS remains a critical neuropsychiatric emergency that warrants vigilant attention. There is a hypothesis proposing that catatonia and NMS may exist along a continuum of the same disorder, and evidence suggests that lorazepam may offer therapeutic benefits for both conditions. It is potential for the concurrent occurrence of NMS and serotonin syndrome when antipsychotics and antidepressants are administered concomitantly. This paper presents a case of NMS following the reinitiation of antipsychotic treatment over an extended duration, a scenario inadequately addressed in existing reports, and discusses strategies for its management in clinical practice.

Abstract

Neuroleptic malignant syndrome (NMS) is a potentially life-threatening idiosyncratic reaction associated with the use of antipsychotic medications, characterized by hyperthermia, muscle rigidity, and alterations in consciousness. Despite a reduction in its incidence due to the predominance of atypical antipsychotics in contemporary treatment regimens, NMS remains a critical neuropsychiatric emergency that warrants vigilant attention. There is a hypothesis proposing that catatonia and NMS may exist along a continuum of the same disorder, and evidence suggests that lorazepam may offer therapeutic benefits for both conditions. It is potential for the concurrent occurrence of NMS and serotonin syndrome when antipsychotics and antidepressants are administered concomitantly. This paper presents a case of NMS following the reinitiation of antipsychotic treatment over an extended duration, a scenario inadequately addressed in existing reports, and discusses strategies for its management in clinical practice.

참고문헌 (35)

  1. Seeman P, "Schizophrenia : more dopamine, more D2 receptors", Proc Natl Acad Sci U S A, 97, pp.7673~7675 (2000)
  2. Pelonero AL, "Neuroleptic malignant syndrome : a review", Psychiatr Serv, 49, pp.1163~1172 (1998)
  3. Stübner S, "Severe and uncommon involuntary movement disorders due to psychotropic drugs", Pharmacopsychiatry, 37(Suppl 1), pp.S54~S64 (2004)
  4. Strawn JR, "Neuroleptic malignant syndrome", Am J Psychiatry, 164, pp.870~876 (2007)
  5. Spivak B, "Prospective evaluation of circulatory levels of catecholamines and serotonin in neuroleptic malignant syndrome", Acta Psychiatr Scand, 102, pp.226~230 (2000)
  6. Ananth J, "Neuroleptic malignant syndrome and atypical antipsychotic drugs", J Clin Psychiatry, 65, pp.464~470 (2004)
  7. Szota AM, "Atypical neuroleptic malignant syndrome : case reports and diagnostic challenges", J Psychoactive Drugs, 54, pp.284~293 (2022)
  8. Kwak YT, "Olanzapine-induced neuroletpic malignant syndrome", J Korean Neurol Assoc, 18, pp.249~251 (2000)
  9. Khaldi S, "Neuroleptic malignant syndrome and atypical antipsychotics: a brief review", Encephale, 34, pp.618~624 (2008)
  10. Zhao H, "Multidisciplinary collaboration in diagnosis and treatment of neuroleptic malignant syndrome complicated with pneumonia : report of three cases", Diagn Pathol, 17, pp.89~ (2022)
  11. Ozaal S, "Exceptionally high creatine kinase levels in risperidone-induced neuroleptic malignant syndrome : a case report", SAGE Open Med Case Rep, 10, pp.2050313X221085096~ (2022)
  12. Hasan S, "Novel antipsychotics and the neuroleptic malignant syndrome : a review and critique", Am J Psychiatry, 155, pp.1113~1116 (1998)
  13. Castelijns MH, "Risperidone-induced severe rhabdomyolysis : a case report", Clin Case Rep Rev, 2, pp.1000241~ (2016)
  14. Kontaxakis VP, "Olanzapine-associated neuroleptic malignant syndrome", Prog Neuropsychopharmacol Biol Psychiatry, 26, pp.897~902 (2002)
  15. Guinart D, "A systematic review and pooled, patient-level analysis of predictors of mortality in neuroleptic malignant syndrome", Acta Psychiatr Scand, 144, pp.329~341 (2021)
  16. American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision(DSM-5-TR)" (2022), American Psychiatric Association Publishing
  17. Funayama M, "Catatonic stupor in schizophrenic disorders and subsequent medical complications and mortality", Psychosom Med, 80, pp.370~376 (2018)
  18. Oldham MA, "The probability that catatonia in the hospital has a medical cause and the relative proportions of its causes : a systematic review", Psychosomatics, 59, pp.333~340 (2018)
  19. White DA, "Catatonia : harbinger of the neuroleptic malignant syndrome", Br J Psychiatry, 158, pp.419~421 (1991)
  20. Fink M, "Neuroleptic malignant syndrome is malignant catatonia, warranting treatments efficacious for catatonia", Prog Neuropsychopharmacol Biol Psychiatry, 30, pp.1182~1183 (2006)
  21. Rogers JP, "Evidence-based consensus guidelines for the management of catatonia : recommendations from the British Association for Psychopharmacology", J Psychopharmacol, 37, pp.327~369 (2023)
  22. Northoff G, "Catatonia and neuroleptic malignant syndrome : psychopathology and pathophysiology", J Neural Transm(Vienna), 109, pp.1453~1467 (2002)
  23. Northoff G, "Orbitofrontal cortical dysfunction in akinetic catatonia : a functional magnetic resonance imaging study during negative emotional stimulation", Schizophr Bull, 30, pp.405~427 (2004)
  24. Rodriguez S, "Neuroleptic malignant syndrome or catatonia? A case report", J Crit Care Med (Targu Mures), 6, pp.190~193 (2020)
  25. Northoff G, "Glutamatergic dysfunction in catatonia? Successful treatment of three acute akinetic catatonic patients with the NMDA antagonist amantadine", J Neurol Neurosurg Psychiatry, 62, pp.404~406 (1997)
  26. Naranjo CA, "A method for estimating the probability of adverse drug reactions", Clin Pharmacol Ther, 30, pp.239~245 (1981)
  27. "The use of the WHO-UMC system for standardised case causality assessment" (2018)[URL]
  28. Adnet P, "Neuroleptic malignant syndrome", Br J Anaesth, 85, pp.129~135 (2000)
  29. Boyer EW, "The serotonin syndrome", N Engl J Med, 352, pp.1112~1120 (2005)
  30. Mazhar F, "Overlapping of serotonin syndrome with neuroleptic malignant syndrome due to linezolidfluoxetine and olanzapine-metoclopramide interactions : a case report of two serious adverse drug effects caused by medication reconciliation failure on hospital admission", Case Rep Med, 2016, pp.7128909~ (2016)
  31. Nisijima K, "Serotonin syndrome overlapping with neuroleptic malignant syndrome : a case report and approaches for differentially diagnosing the two syndromes", Asian J Psychiatr, 18, pp.100~101 (2015)
  32. Richter A, "Lorazepam modulates orbitofrontal signal changes during emotional processing in catatonia", Hum Psychopharmacol, 25, pp.55~62 (2010)
  33. Pileggi DJ, "Neuroleptic malignant syndrome", Ann Pharmacother, 50, pp.973~981 (2016)
  34. Ross C, "Successful clozapine rechallenge following clozapine-induced neuroleptic malignant syndrome", Mental Health Clinician, 5, pp.88~90 (2015)
  35. Modi S, "Neuroleptic malignant syndrome : complications, outcomes, and mortality", Neurocrit Care, 24, pp.97~103 (2016)

이 간행물의 다른 논문 (5건)

정신증 고위험군과 최근 발병한 정신증 치료의 최신 지견박선영, 이지성, 조영탁, 박일호, 이중선pp. 35-48조현병에서 경두개 자기 자극 치료김민아, 박성현, 장문영, 권준수pp. 49-56다유전자 위험 점수를 이용한 한국인 조현병, 양극성 장애 및 정상 대조군 간의 유전적 조형 비교이동은, 이현주, 홍경수, 하태현, 백지현, 김성완, 하규섭, 이헌정, 조은영, 명우재, 최민준, 안용민pp. 57-62조현병 외래 환자의 개인적 회복 관련 요인김철권, 김준기pp. 63-71조현병 환자에서 성별에 따른 인지기능의 차이최말례, 신예은, 한명일, 박경환pp. 72-77
원문 보기